These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 6151123

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
    Nilsson CL, Brinkmalm A, Minthon L, Blennow K, Ekman R.
    Peptides; 2001 Dec; 22(12):2105-12. PubMed ID: 11786197
    [Abstract] [Full Text] [Related]

  • 9. Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia.
    Minthon L, Edvinsson L, Gustafson L.
    Dement Geriatr Cogn Disord; 1997 Dec; 8(4):232-9. PubMed ID: 9213068
    [Abstract] [Full Text] [Related]

  • 10. Reduced lumbar CSF somatostatin levels in Alzheimer's disease.
    Wood PL, Etienne P, Lal S, Gauthier S, Cajal S, Nair NP.
    Life Sci; 1982 Nov 08; 31(19):2073-9. PubMed ID: 6184590
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease.
    Johansson A, Zetterberg H, Håkansson A, Nissbrandt H, Blennow K.
    Neurodegener Dis; 2005 Nov 08; 2(1):28-35. PubMed ID: 16909000
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.
    Biol Psychiatry; 2008 Nov 15; 64(10):850-5. PubMed ID: 18395699
    [Abstract] [Full Text] [Related]

  • 15. Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes.
    Beal MF, Clevens RA, Mazurek MF.
    Synapse; 1988 Nov 15; 2(4):463-7. PubMed ID: 2903567
    [Abstract] [Full Text] [Related]

  • 16. Characterization of the course of senile dementia of the Alzheimer type using cerebrospinal fluid levels of acetylcholinesterase and somatostatin.
    Urakami K, Adachi Y, Awaki E, Takahashi K.
    Acta Neurol Scand; 1989 Sep 15; 80(3):232-7. PubMed ID: 2572139
    [Abstract] [Full Text] [Related]

  • 17. Somatostatin-like immunoreactivity in lumbar cerebrospinal fluid from neurohistologically examined demented patients.
    Francis PT, Bowen DM, Neary D, Palo J, Wikstrom J, Olney J.
    Neurobiol Aging; 1984 Sep 15; 5(3):183-6. PubMed ID: 6151122
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls.
    Hartikainen P, Reinikainen KJ, Soininen H, Sirviö J, Soikkeli R, Riekkinen PJ.
    J Neural Transm Park Dis Dement Sect; 1992 Sep 15; 4(1):53-68. PubMed ID: 1347220
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.